Jan 26, 2023 8:30am EST Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
Nov 08, 2022 8:00am EST Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Sep 22, 2022 9:00am EDT Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
Sep 07, 2022 8:30am EDT Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 16, 2022 9:00am EDT Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
Aug 09, 2022 8:10am EDT Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 19, 2022 9:07am EDT Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Jun 27, 2022 8:30am EDT Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Jun 24, 2022 8:30am EDT Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
